Achilles Therapeutics Cash Per Share vs. Return On Equity

ACHL Stock  USD 1.05  0.01  0.96%   
Based on Achilles Therapeutics' profitability indicators, Achilles Therapeutics PLC may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Achilles Therapeutics' ability to earn profits and add value for shareholders.
 
Cash Per Share  
First Reported
2010-12-31
Previous Quarter
3.29069136
Current Value
3.13
Quarterly Volatility
13.68392398
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, Achilles Therapeutics' Income Quality is quite stable compared to the past year. Current Ratio is expected to rise to 15.18 this year, although Book Value Per Share will most likely fall to 3.38.
For Achilles Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Achilles Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Achilles Therapeutics PLC utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Achilles Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Achilles Therapeutics PLC over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achilles Therapeutics. If investors know Achilles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achilles Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.66)
Return On Assets
(0.27)
Return On Equity
(0.44)
The market value of Achilles Therapeutics PLC is measured differently than its book value, which is the value of Achilles that is recorded on the company's balance sheet. Investors also form their own opinion of Achilles Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Achilles Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achilles Therapeutics' market value can be influenced by many factors that don't directly affect Achilles Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Achilles Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Achilles Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achilles Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Achilles Therapeutics PLC Return On Equity vs. Cash Per Share Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Achilles Therapeutics's current stock value. Our valuation model uses many indicators to compare Achilles Therapeutics value to that of its competitors to determine the firm's financial worth.
Achilles Therapeutics PLC is rated second in cash per share category among its peers. It is rated third in return on equity category among its peers . At this time, Achilles Therapeutics' Cash Per Share is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Achilles Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Achilles Return On Equity vs. Cash Per Share

Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Achilles Therapeutics

Cash Per Share

 = 

Total Cash

Average Shares

 = 
4.94 X
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Achilles Therapeutics

Return On Equity

 = 

Net Income

Total Equity

 = 
-0.44
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.

Achilles Return On Equity Comparison

Achilles Therapeutics is currently under evaluation in return on equity category among its peers.

Achilles Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Achilles Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Achilles Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Achilles Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Achilles Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-13.1 M-12.4 M
Net Loss-64.1 M-60.9 M
Operating Income-75.3 M-79 M
Net Loss-75.1 M-78.8 M
Income Before Tax-69.2 M-72.6 M
Total Other Income Expense Net6.1 M3.7 M
Net Loss-69.9 M-66.4 M
Income Tax Expense491 K515.5 K
Change To Netincome16 M16.8 M
Net Loss(1.74)(1.83)
Income Quality 0.69  0.99 
Net Income Per E B T 1.01  0.80 

Achilles Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Achilles Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Achilles Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Achilles Therapeutics' important profitability drivers and their relationship over time.

Use Achilles Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Achilles Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Achilles Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Achilles Therapeutics Pair Trading

Achilles Therapeutics PLC Pair Trading Analysis

The ability to find closely correlated positions to Achilles Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Achilles Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Achilles Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Achilles Therapeutics PLC to buy it.
The correlation of Achilles Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Achilles Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Achilles Therapeutics PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Achilles Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Achilles Therapeutics position

In addition to having Achilles Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Theme ETFs Thematic Idea Now

Theme ETFs
Theme ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Theme ETFs theme has 484 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Theme ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Achilles Therapeutics PLC is a strong investment it is important to analyze Achilles Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Achilles Therapeutics' future performance. For an informed investment choice regarding Achilles Stock, refer to the following important reports:
Check out Trending Equities.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
To fully project Achilles Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Achilles Therapeutics PLC at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Achilles Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Achilles Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Achilles Therapeutics investors may work on each financial statement separately, they are all related. The changes in Achilles Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Achilles Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.